Latest Conference Coverage

Potential of Neuropalliative Care Evaluated for Patients With Drug-Resistant Epilepsy

Investigators suggest further studies to better determine is NPC had measurable benefits for patient quality of life.

Cenobamate Offers Unique Benefit for Surgically Refractory Epilepsy

Across all surgical procedures, the percentage of patients with seizure freedom for at least 12 months ranged from 20% to 35.7% for patients receiving cenobamate.

Vaccination and Seizure Risk in Dravet Syndrome: Veronica Hood, PhD, MS

The scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]

Perampanel Shows Real-World Benefit in Epilepsy With Comorbid Intellectual Disability

In total, 6.4% of those with intellectual disability achieved seizure freedom and 37.5% had at least a 50% responder rate after treatment with perampanel.

Cementing an Understanding of Managing Seizures in Elders With Epilepsy

While typically thought of as a disease that affects younger populations, Rebecca O’Dwyer, MD, stressed the importance and nuances of caring for older adults with epilepsy.

COVID-19 Vaccination in Patients with Dravet Syndrome: Veronica Hood, PhD, MS

The scientific director at the Dravet Syndrome Foundation discussed a recent survey asking caregivers about the experiences of patients with DS following COVID-19 vaccination. [WATCH TIME: 3 minutes]

VNS Implantation, Dietary Therapies Reduce Seizures in Children With TSC, DRE

Findings presented at AES 2021 included data from children with tuberous sclerosis complex and drug refractory epilepsy who were not candidates for epilepsy surgery.

Ganaxolone Associated With Decreased Seizure Frequency in Patients With CDD, LGS

Four out of 6 patients with CDKL5 deficiency disorder and comorbid Lennox-Gastaut syndrome had a decrease in frequency of major motor seizures when treated with ganaxolone.

CBTip Demonstrates Pronounced Results in Psychogenic Nonepileptic Seizures

Half of the patients who were on a flexible, longer-term Cognitive Behavioral Therapy-informed psychotherapy treatment schedule demonstrated improvements in seizure frequency by more than 50%.

Perampanel Further Demonstrates Efficacy, Safety in Large Real-World Analysis

At the 12-month mark, more than 64% of patients had remained on perampanel, with an overall mean retention time of 10.8 months.

Exploring the Benefits of CBT for Psychogenic Non-Epileptic Seizures: Becky Tilahun, PhD

The clinical psychologist at Cleveland Clinic discussed the potential of using cognitive behavioral therapy for treatment of psychogenic non-epileptic seizures on cognitive behavioral therapy. [WATCH TIME: 3 minutes]

Perampanel Effective, Well-Tolerated in Lennox-Gastaut Syndrome

Findings were presented at AES 2021, with 56.7% of patients reporting a 50% or greater reduction in seizure frequency.

Prednisolone Improves Seizure Outcomes in Infantile Spasms After Vigabatrin Failure

More than two-thirds of patients who received prednisolone after showing no response to vigabatrin demonstrated complete electroclinical response at 2 weeks, with most sustaining response at 6 weeks.

Patient Feedback on Telehealth: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the positive feedback from patients when discussing telehealth. [WATCH TIME: 4 minutes]

Masupirdine Improves Agitation and Aggression in Alzheimer Disease

A phase 3 trial has been initiated to further study masupirdine’s effect on agitation in patients with Alzheimer dementia.

Future Integration, Coverage for Telemedicine in Multiple Sclerosis: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed the necessary data to support telemedicine’s integration into clinical care. [WATCH TIME: 4 minutes]

Lecanemab Reduces Amyloid in Patients With Early Alzheimer Disease

Data show a clinical benefit via a reduction in brain amyloid as early as 3 months in the open-label extension period.

Choosing Therapies for Patients With MS: Devon Conway, MD

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic outlined the process of choosing a therapy for patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Tackling Multiple Sclerosis With Combination Treatment Approaches, Biomarkers: Jeffrey Cohen, MD

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the possibility of using multiple DMTs to combat the effects of MS. [WATCH TIME: 3 minutes]

Key Takeaways From a Study of FUS in Early AD Dementia: Ali Rezai, MD

The executive chair at the Rockefeller Neuroscience Institute at West Virginia University shed light on early data from a small sample of patients with early Alzheimer disease who underwent focused ultrasound treatment. [WATCH TIME: 5 minutes]

Choosing Treatments for Patients With Multiple Sclerosis: Devon Conway, MD

Discussing newer treatment options in the MS field, the staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic noted that patient preference can play a part in the decision-making process. [WATCH TIME: 3 minutes]

New Medications for Multiple Sclerosis Treatment: Devon Conway, MD

The staff neurologist in the Neurological Institute’s Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed emerging treatments in the MS field. [WATCH TIME: 2 minutes]

Next Steps, Future Development of FUS Technology in Alzheimer Disease: Ali Rezai, MD

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University discussed the potential of focused ultrasound for patients with AD, as well as key takeaways for clinicians from a recent study. [WATCH TIME: 5 minutes]

Low-Dose Lithium Shows Mixed Benefits for Alzheimer, Fails to Improve Behavioral Complications

Despite not being significantly superior to placebo on agitation and aggression, lithium showed a greater reduction in those with high Young Mania Rating Scale scores.

CMSC 2021: Top Interviews and Key Takeaways

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Evaluating Early Data on Focused Ultrasound for Patients With Alzheimer Disease

Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.

Applications of MRI-Guided FUS in Alzheimer Disease: Ali Rezai, MD

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]

Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology

The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.

UC San Diego Health: Institutional Perspectives in Neurology, Chaired by Jennifer Graves, MD, PhD, MAS

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Investigating the Use of MRI-Guided Focused Ultrasound in Alzheimer Disease

Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.